Malgorzata Bajor

Nielubowicza 5 Street
Warsaw, MZ 02097, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Correction to: GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis.

Correction to: GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis.

Journal: Cancer immunology, immunotherapy : CII

Published: April 07, 2026

GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis.

GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis.

Journal: Cancer immunology, immunotherapy : CII

Published: April 25, 2025

Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors.

Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors.

Journal: HemaSphere

Published: January 10, 2023

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.

Journal: Journal for immunotherapy of cancer

Published: December 19, 2021

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance.

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance.

Journal: Cancers

Published: November 03, 2021

PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress.

PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress.

Journal: Cancer immunology research

Published: December 23, 2020

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells.

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells.

Journal: Antioxidants (Basel, Switzerland)

Published: February 28, 2020

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer.

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer.

Journal: Cancers

Published: October 04, 2019

Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy.

Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy.

Journal: Cancer letters

Published: October 01, 2019

Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate.

Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate.

Journal: Redox biology

Published: August 17, 2018

Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.

Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.

Journal: British journal of cancer

Published: March 23, 2018

Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells.

Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells.

Journal: Haematologica

Published: February 03, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026